London, Feb 12, 2026, 09:39 GMT — Regular session
- Haleon shares slipped at the open in London, with investors digesting new ownership disclosures and eyeing upcoming results.
- Wellington Management has revealed a stake just shy of 5% in the consumer health group, according to a U.S. filing.
- Next up: Haleon’s full-year results drop Feb. 25, marking the next major checkpoint for guidance and cash returns.
Haleon (HLN.L) slipped Thursday, with shares off roughly 0.4% at 404.6 pence by 0939 GMT. Investors reacted after a U.S. filing revealed Wellington Management owns close to 5% of the consumer healthcare group.
The clock’s ticking for Haleon, with full-year numbers due Feb. 25. Investors are looking for fresh guidance and clarity on cash returns. Behind the scenes, quite a bit of reshuffling has taken place in big UK defensives ahead of that date.
Macro signals are getting louder. The U.K. economy barely edged up, with a 0.1% gain in the fourth quarter—underwhelming expectations and fueling more chatter about possible rate cuts. “There were some tentative signs that sentiment turned a corner … after the budget,” said Luke Bartholomew, deputy chief economist at Aberdeen. Reuters
Wellington Management Group, along with affiliated entities, disclosed in an amended Schedule 13G/A filed Feb. 10 that it held 443,046,686 shares of Haleon—amounting to 4.97%—as of Dec. 31. The Schedule 13G filing is typically the route for passive investors to notify markets of sizable stakes without indicating activist intentions.
Haleon reported share deals by two of its top executives as part of its reward scheme. General Counsel Adrian Morris and Europe President Jonathan Workman each picked up small batches of “partnership” shares at 3.956 pounds, the company said, and received matching shares for free. In the UK, PDMR refers to senior managers whose trades need to be disclosed. TradingView
Haleon kicked off Thursday at 405.9 pence, moving within a range from 401.4 to 406.7 pence during the session. The stock last closed at 406.3 pence.
Haleon snapped into the session riding a two-day winning streak. The stock picked up 2.04% to close at 4.00 pounds on Tuesday, outperforming a falling FTSE 100—even as volume lagged the average, according to MarketWatch data.
The FTSE 100 in London locked in a fresh record close Wednesday, lifted by gains in homebuilder and energy shares. “The mainstream housebuilders… are likely to be the major winners,” RBC’s Anthony Codling and his team said in a sector note. Reuters
Haleon, maker of Sensodyne toothpaste as well as Panadol and Advil painkillers, stands shoulder to shoulder with Reckitt and Kenvue in the everyday-health segment. Eyes turn to the Feb. 25 print, where investors zero in on volume and pricing—and start measuring just how resilient demand could be going into 2026.
Still, a stake disclosure or a handful of executive share awards rarely shifts the business trajectory by itself—they tend to be forgotten quickly. What really matters is guidance: a cautious outlook, or any sign of weaker consumer demand than anticipated, poses a more serious downside risk.
Eyes now turn to Feb. 25, when Haleon delivers its full-year numbers. Investors want to see what the company signals for 2026, plus any word on dividends or buybacks. Management’s take on growth in those top markets will also get scrutiny.
